晚期上皮性卵巢癌间歇性减瘤术联合HIPEC的微创与开腹手术可行性和围手术期结局比较
微创组住院时间更短(3天 vs 4天,p=0.016),R0切除率、30天不良事件及无复发生存无显著差异。研究表明新辅助化疗后间歇性减瘤术联合HIPEC时采用微创入路可行,不应妨碍HIPEC的应用。
要点
- 微创组与开腹组R0切除率无差异(70.0% vs 77.5%,p=0.39)
- 微创组住院时间更短(3天 vs 4天,p=0.016)
- 两组无复发生存无显著差异(中位15.0 vs 17.2个月,p=0.30)
核心结论
- 新辅助化疗后间歇性减瘤术联合HIPEC时采用微创入路可行,R0切除率与开腹相似。
- 微创入路不应妨碍外科医生在晚期上皮性卵巢癌有指征时使用HIPEC。
研究设计与样本
- 单中心回顾性队列研究,纳入2017至2019年接受间歇性减瘤术联合HIPEC的晚期上皮性卵巢癌女性。
- 围手术期结局采用单因素分析比较。
主要发现
- 微创组中位年龄71.1岁,开腹组64.2岁(p=0.031)。
- 新辅助化疗后术前完全影像学缓解率两组无显著差异(p=0.18)。
- R0切除率微创组70.0%、开腹组77.5%(p=0.39)。
- ICU入住、估计失血量、手术时间及血管升压药使用两组无显著差异。
- 30天不良事件两组无差异,但微创组住院时间更短(3天 vs 4天,p=0.016)。
关键数值与推荐
- R0切除率:微创组70.0%,开腹组77.5%(p=0.39)。
- 住院时间:微创组3天,开腹组4天(p=0.016)。
- 术后化疗启动时间:微创组26.2天,开腹组32.0天(p=0.090)。
- 中位随访15.1个月,无复发生存中位微创组15.0个月、开腹组17.2个月(log-rank p=0.30)。
临床怎么用
- 对新辅助化疗后适合间歇性减瘤术的晚期上皮性卵巢癌患者,可考虑微创入路联合HIPEC。
- 微创入路可能缩短住院时间,且不增加30天不良事件。
- 微创入路不应成为实施HIPEC的障碍。
局限性
- 微创组年龄显著高于开腹组,可能存在选择偏倚。
- 中位随访时间较短(15.1个月)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To determine peri-operative outcomes in women with advanced epithelial ovarian cancer (EOC) undergoing interval debulking surgery (IDS) with hyperthermic intraperitoneal chemotherapy (HIPEC) via minimally invasive interval debulking surgery (MIS) or laparotomy (LAP). METHODS: A single institution, retrospective cohort study was performed in women with EOC who underwent IDS with HIPEC from 2017 to 2019 via MIS or LAP. Peri-operative outcomes were compared using univariate analysis. RESULTS: In total, 50 eligible women were identified; ten (20.0%) underwent MIS + HIPEC and 40 (80.0%) LAP + HIPEC. The median age of patients in the MIS group was 71.1 vs. 64.2 years in LAP (p = 0.031). There was no significant difference in pre-operative complete radiographic response following NACT (p = 0.18). Notably, there was no difference in the rate of R0 resection (70.0% vs. 77.5%; p = 0.39). There was no significant difference in ICU admission, estimated blood loss, operative time, or use of vasopressors between the cohorts. Similarly, there was no difference in 30-day adverse events for MIS vs. LAP, but length of stay was decreased for those who underwent minimally invasive procedures (3 vs. 4 days, p = 0.016). Time to initiation of chemotherapy following surgery was not significantly different between groups (26.2 days vs 32.0 days, p = 0.090). With median follow-up of 15.1 months, there was no difference in recurrence free survival (median 15.0 vs 17.2 months log-rank, p = 0.30) for MIS vs. LAP. CONCLUSIONS: In this retrospective cohort study, we demonstrate that in women with advanced EOC, HIPEC with MIS at the time of IDS following NACT is feasible. Our institutional experience demonstrates similar rates of R0 cytoreduction, compared to LAP. An MIS approach should not prevent surgeons from utilizing HIPEC where indicated for management of advanced EOC.
引用
- Morton M, Chambers LM, Costales AB, et al. Assessing feasibility and perioperative outcomes with minimally invasive surgery compared with laparotomy for interval debulking surgery with hyperthermic intraperitoneal chemotherapy for advanced epithelial ovarian cancer. Gynecol Oncol. 2020. PMID: 33067001. doi:10.1016/j.ygyno.2020.09.052
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。